• Y Gillet, O Dumitrescu, A Tristan, O Dauwalder, E Javouhey, D Floret, F Vandenesch, J Etienne, and G Lina.
• Division of Pediatric Intensive Care, Hôpital Femme Mère Enfant, Bron, France.
• Int. J. Antimicrob. Agents. 2011 Dec 1; 38 (6): 457-64.

AbstractPanton-Valentine leukocidin (PVL)-producing Staphylococcus aureus is associated with a broad spectrum of diseases, ranging from common uncomplicated soft tissue infections to severe diseases such as complicated soft tissue infections, extensive bone and joint infections, and necrotising pneumonia. Specialised management of infection based on the presence of PVL may not be required for mild infections, whereas it could be lifesaving in other settings. Moreover, most severe PVL diseases are recently identified entities and a 'gold standard' treatment from comparatives studies of different therapeutic options is lacking. Thus, recommendations are based on expert opinions, which are elaborated based on theory, in vitro data and analogies with other toxin-mediated diseases. In this review, we consider the potential need for specialised PVL-based management and, if required, which tools should be used to achieve optimal management.Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

19 keywords...

hide…